ACOR News and Press, Acorda Therapeutics Inc. From 05/21/23

2023-05-21 19:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-05-14 14:20:00 ET Summary Bliss Biopharma (Hangzhou) announced it may out-license global rights (ex-China) for its HER2 ADC to Japan’s Eisai Pharma in a deal with a potential value of $2 billion. Shanghai Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to...

2023-05-12 03:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-05-11 20:22:10 ET Acorda Therapeutics, Inc. (ACOR) Q1 2023 Earnings Conference Call May 11, 2023, 16:30 ET Company Participants Tierney Saccavino - EVP, Corporate Communications Ron Cohen - Founder, CEO, President & Director Michael Gesser - CFO Co...

2023-05-11 16:02:55 ET Acorda Therapeutics press release ( NASDAQ: ACOR ): Q1 GAAP EPS of -$0.69 beats by $0.42 . Revenue of $22.25M (-1.2% Y/Y) misses by $8.76M . For further details see: Acorda Therapeutics GAAP EPS of -$0.69 beats by $0.42, revenue of ...

INBRIJA ® (levodopa inhalation powder) Q1 2023 U.S. net revenue of $5.6 million, a 52% increase from Q1 2022; ex-U.S. net revenue of $0.5 million AMPYRA ® (dalfampridine) Extended Release Tablets, 10 mg Q1 2023 net revenue of $12.6 million, a 15% decrease from Q1 2022; FAMPY...

2023-05-10 07:37:26 ET Acorda Therapeutics ( NASDAQ: ACOR ) will make a cash interest payment of ~$6.2M due on June 1, 2023 under its convertible senior secured notes indenture. The company will make the interest payment using cash that was placed in escrow when the notes ...

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will make a cash interest payment of approximately $6.2 million due on June 1, 2023 under its Convertible Senior Secured Notes Indenture. Under the terms of the Indenture, Acorda may elect to make interest payments under the Ind...

2023-05-09 08:45:27 ET Palm Beach, FL – May 9, 2023 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is a progressive and neurodegenerative disorder that attacks the brain’s nerve cells or neurons, which results in loss of memory, th...

2023-05-08 09:48:32 ET Acorda Therapeutics ( NASDAQ: ACOR ) and Hangzhou Chance Pharmaceuticals announced a distribution and supply agreement for INBRIJA in China. ( ACOR ) is up 7% . INBRIJA is used in the United States for treating adult patients with Parkinson's d...